Vericel

Traded on the St. Petersburg Stock Exchange
Vericel Corporation is a biopharmaceutical company.
Vericel stock price chart
+63%
P/E adj.
Net profit (adj.)
P/B
Book value
P/FCF
FCF
Yield
Growth potential

Vericel balance sheet

Report period2018 2019 2020 2021 2022 Q3 23
End date of the reporting period
Capitalization, $
Capitalization, $
Enterprise Value
Book Value
Shareholders Book Value
Current liabilities
Noncurrent liabilities
Total liabilities
Debt
Cash and cash equivalents
Net debt
Assets
Total ordinary shares
Ordinary share price

Vericel cash flows

Report period2018 2019 2020 2021 2022 Q3 23 TTM
End date of the reporting period
Sales
Gross profit
Operation Income
Earnings
Shareholders earnings
Adjusted Earnings
EBITDA
Adjusted EBITDA
Operation Cashflow
Capital expenditure
Free Cash Flow
EPS
Adjusted EPS

Vericel multipliers

Report period2018 2019 2020 2021 2022 Q3 23 TTM
P/E
P/E adj.
E/P
E adj./P
P/B
P/S
P/FCF
L/A
Debt-To-Equity
Net Debt/EBITDA
Net Debt/EBITDA adj.
EV/EBITDA
EV/EBITDA adj.

Vericel profitability

Report period2018 2019 2020 2021 2022 Q3 23 TTM
ROA
ROE
ROS
Gross margin
EBITDA Margin
Operating margin
Vericel assets
Vericel cash flows

Vericel shares

TickerNameTypeNominal valueISINPrice
VCEL:USVericel Corp.Common share-US92346J1088$46.9
Vericel news
04.05.2022
The loss of Vericel under GAAP for the 3 months of 2022 was $7.091 million, up 2.2 times from $3.289 million in the previous year. Revenue increased by 4.4% to $36.074 million from $34.568 million a year earlier.
24.02.2022
Vericel's GAAP loss for 2021 was $7.471 million, compared to a profit of $2.864 million in the previous year. Revenue increased 25.8% to $156.184 million from $124.179 million a year earlier.
09.11.2021
Vericel's GAAP loss for 9M 2021 was $12.006 million, up 28.3% from $9.356 million in the previous year. Revenue increased 37.5% to $108.593 million from $78.95 million a year earlier.
04.08.2021
Vericel's GAAP loss for 6 months of 2021 was $7.075 million, down 45.5% from $12.974 million in the previous year. Revenue increased 58.7% to $74.087 million from $46.692 million a year earlier.
General information
Company nameVericel
SectorHealth Care / Pharmaceuticals, Biotechnology & Life Sciences / Life Sciences Tools & Services / Life Sciences Tools & Services
Business address64 SIDNEY ST. CAMBRIDGE MA 02139 7349305555
Mailing address64 SIDNEY ST. CAMBRIDGE MA 02139
Websitewww.vcel.com
Information disclosurewww.sec.gov